Curing chronic hepatitis B virus infection

In The Lancet Infectious Diseases, Man-Fung Yuen and colleagues 1 Yuen M-F Balabanska R Cottreel E et al. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2022; (published online Dec 9.)https://doi.org/10.1016/S1473-3099(22)00727-7 Summary Full Text Full Text PDF PubMed Scopus (4) Google Scholar have published a study investigating the safety and tolerability of different doses of RO7020531, an oral prodrug of a toll-like receptor 7 (TLR7) agonist, in healthy volunteers and in patients with chronic hepatitis B virus (HBV) infection. Findings from this randomised, placebo-controlled trial are indispensable to aid in further development of this oral TLR7 agonist, which could be added to the arsenal of strategies aimed at curing chronic HBV infection. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trialDue to acceptable safety and tolerability, RO7020531 should continue to be developed for the treatment of patients with chronic HBV infection. Full-Text PDF